Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on X:
“How I think about 1st line HER2+ Metastatic Breast Cancer.
Decision 1: THP versus T-DXd + P
Decision 2: Maintenance based on receptor status”
To which Carlos Gonzalez, Medical Oncologist focused in Breast Cancer at the National Cancer Institute, added:
“Makes so much sense. Thanks Dr. Sarah Sammons.”
Other articles featuring Sarah Sammons on OncoDaily.